| Literature DB >> 32344861 |
Victor Murcia Pienkowski1, Marzena Kucharczyk2, Małgorzata Rydzanicz1, Barbara Poszewiecka3, Katarzyna Pachota2, Marlena Młynek2, Piotr Stawiński1, Agnieszka Pollak1, Joanna Kosińska1, Katarzyna Wojciechowska4, Monika Lejman5, Agata Cieślikowska2, Dorota Wicher2, Agnieszka Stembalska6, Karolina Matuszewska7,8, Anna Materna-Kiryluk7,8, Anna Gambin3, Krystyna Chrzanowska2, Małgorzata Krajewska-Walasek2, Rafał Płoski1.
Abstract
De novo balanced chromosomal aberrations (BCAs), such as reciprocal translocations and inversions, are genomic aberrations that, in approximately 25% of cases, affect the human phenotype. Delineation of the exact structure of BCAs may provide a precise diagnosis and/or point to new disease loci. We report on six patients with de novo balanced chromosomal translocations (BCTs) and one patient with a de novo inversion, in whom we mapped breakpoints to a resolution of 1 bp, using shallow whole-genome mate pair sequencing. In all seven cases, a disruption of at least one gene was found. In two patients, the phenotypic impact of the disrupted genes is well known (NFIA, ATP7A). In five patients, the aberration damaged genes: PARD3, EPHA6, KLF13, STK24, UBR3, MLLT10 and TLE3, whose influence on the human phenotype is poorly understood. In particular, our results suggest novel candidate genes for retinal degeneration with anophthalmia (EPHA6), developmental delay with speech impairment (KLF13), and developmental delay with brain dysembryoplastic neuroepithelial tumor (UBR3). In conclusion, identification of the exact structure of symptomatic BCTs using next generation sequencing is a viable method for both diagnosis and finding novel disease candidate genes in humans.Entities:
Keywords: EPHA6; KLF13; UBR3; de novo balanced aberrations; developmental delay; mate-pair sequencing
Year: 2020 PMID: 32344861 PMCID: PMC7287862 DOI: 10.3390/jcm9051245
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Summary of the results of all the patients.
| Proband | Karyotyping Results | Break-Point Positions | Phenotype | Disrupted Gene(s) |
|---|---|---|---|---|
| 1 | 46,XY,t(3;5)(q11.2;p13.1) | chr3:96,955,385/chr5:30,867,535 | Developmental delay, anophthalmia | |
| 2 | 46,XY, t(8;10)(p22;p11.21) | chr10:34,546,389/chr8:12,996,881 | Hypotonia, dysmorphic features | |
| 3 | 46,XY,t(1;2)(p31.3;q33.1) | chr1:61,754,634/chr2:200,725,835 | Developmental delay | |
| 4 | 46,XX,inv(2)(q31.1;q37.3) | chr2:170,714,752/chr2:239,263,182 | Severe mental retardation, cured brain dysembryoplastic neuroepithelial tumor | |
| 5 | 46,X,t(X;1)(q21.1;p21.1) | chrX:77,213,561/chr1:106,152,109 | Menkes disease | |
| 6 | 46,XX,t(10;15)(p12.31;q23) | chr10:21,972,544/chr15:70,361,328 | Speech delay | |
| 7 | 46,XX,t(13;15)(q32.2;q13.3) | chr13:99,169,136/chr15:31,620,350 | Developmental delay |
Figure 1Results from Sanger sequencing and/or deep amplicon sequencing with NexteraXT library of the balanced chromosomal aberrations (BCAs) breakpoints. The figure for every patient includes: in the upper part, a schematically shown normal chromosome and below a chromosome containing the BCAs. Arrows indicate the orientation of the genes affected by translocation. The length of the arrows approximately corresponds to the length of the disrupted coding sequences. The lower part shows the sequencing results. For every BCA, both breakpoints are shown. In deep amplicon sequencing results, only split reads are shown (reads that present the exact structure of the breakpoint). One part of these reads fully maps to the reference genome, while the other part differs from the reference. In Proband 2 an inframe fusion gene might be created.